Nyrada (ASX:NYR) received approval from the Human Research Ethics Committee to start its first-in-human phase 1a clinical trial evaluating the safety, tolerability, and pharmacokinetics of drug candidate NYR-BI03, according to a Friday filing with the Australian bourse.
NYR-BI03 is a treatment that has the potential to protect both brain and heart tissue.
The double-blind, randomized, placebo-controlled study will administer either NYR-BI03 or placebo to five groups of eight healthy volunteers, with six active and two placebo participants per group, the filing said.
The first dosing is expected to begin by the end of March, according to the filing.
Nyrada's shares were up 5% in afternoon trade Friday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。